Cover Image
市場調查報告書

阿茲海默症的治療、診斷市場 (2017-2027年):主要的治療藥、開發平台治療藥、生物標記、主要企業

Alzheimer's Disease Therapeutics and Diagnostics Market 2017-2027: Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies

出版商 Visiongain Ltd 商品編碼 288683
出版日期 內容資訊 英文 207 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
阿茲海默症的治療、診斷市場 (2017-2027年):主要的治療藥、開發平台治療藥、生物標記、主要企業 Alzheimer's Disease Therapeutics and Diagnostics Market 2017-2027: Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies
出版日期: 2017年09月21日 內容資訊: 英文 207 Pages
簡介

2016年的全球阿茲海默症治療藥、診斷市場規模達到了67億1,000萬美元。該市場預計至預測期間的後半,以15.3%的年複合成長率擴大。

本報告提供阿茲海默症的治療藥及診斷市場相關調查,治療藥市場定量分析,主要治療藥、開發平台治療藥的分析與預測,診斷市場定量分析,主要企業的簡介,主要國家市場,及專家的採訪等彙整資料。

第1章 報告概要

第2章 阿茲海默症:簡介

  • 神經退化性疾病
    • 所謂阿茲海默症
    • 原因
    • 管理
    • 社會經濟影響
    • 診斷

第3章 阿茲海默症的治療藥、診斷市場

  • 阿茲海默症的治療、診斷市場:成果
  • 阿茲海默症的治療、診斷市場預測
  • 促進成長要素、阻礙要素
  • 對早期疾病的關注變化

第4章 阿茲海默症治療藥:市場預測

  • 阿茲海默症的治療的現在的方法和未滿足需求
  • 阿茲海默症治療藥:市場成果
  • 主要的阿茲海默症治療藥佔有率的變化與預測
  • 阿茲海默症治療藥市場預測
  • Namenda
  • Aricept
  • Exelon
  • 阿茲海默症治療藥開發平台
  • 腦深部刺激 (功能的神經調節)
  • 阿茲海默症相關近幾年的研究

第5章 老年癡呆症治療藥市場上主要企業

  • Pfizer, Inc
  • Eisai
  • Forest Laboratories (Acquired by Actavis)
  • Lundbeck A/S
  • 第一三共
  • Novartis AG
  • TauRx
  • vTv Therapeutics

第6章 阿茲海默症診斷市場

  • 對有效診斷的大需求
  • 阿茲海默症診斷市場:成果
  • 主要的阿茲海默症診斷市場市場佔有率的變化與預測
  • 阿茲海默症診斷市場:成果與預測
  • 阿茲海默症診斷的新標準和指南
  • 生物標記
    • 主要企業
  • 診斷影像技術的進步
    • 結構影像
    • 功能影像
    • 分子影像技術
  • 開發中的其他診斷技術
    • CSF蛋白質
    • 血液為基礎的生物標記
    • 遺傳的風險分析
    • 眼睛檢查
    • 奈米粒子
  • 診斷市場主要企業
    • Eli Lilly
    • Amarantus BioScience Holdings, Inc.
    • Piramal Enterprises
    • GE Healthcare
    • Navidea
    • DiaGenic

第7章 主要國家市場預測

  • 市場成果:各地區明細
  • 市場預測:各地區明細
  • 主要國家市場的市場佔有率的變化、預測
  • 美國
  • 歐洲
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 英國
    • 其他
  • 日本
  • 中國
  • 印度
  • 巴西
  • 俄羅斯
  • 其他

第8章 阿茲海默症的定性分析:治療藥、診斷市場

  • SWOT分析
  • 優勢
  • 弱點
  • 機會
  • 威脅
  • 波特的五力分析

第9章 專家的見解

第10章 總論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0241

The Alzheimer's Disease Therapeutics and Diagnostics Market reached $6.71bn in 2016. The Alzheimer's Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 15.3% in the second half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 207-page report you will receive 73 tables and 76 figures- all unavailable elsewhere.

The 207-page report provides clear detailed insight into the Alzheimer's Disease Therapeutics and Diagnostics Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Alzheimer's Disease Market forecasts from 2017-2027, further broken down into:
    • Alzheimer's Drugs Market
    • Alzheimer's Diagnostics Market
  • Quantitative analysis of the Alzheimer's drug market from 2017 to 2027. It includes analysis and forecast of top drugs and pipeline drugs in the market:
    • Namenda
    • Aricept
    • Exelon
    • Solanezumab
    • Gantenerumab
    • Verubecestat
  • Quantitative analysis of the Alzheimer's diagnostics market from 2017 to 2027. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer's diagnosis from 2017to 2027:
    • Diagnostic biomarker market
    • Others
  • Profiles of leading pharma companies involved in developing Alzheimer's drugs globally. It contains overviews of the companies' segments, recent mergers and acquisitions and analysis of the companies' recent financial performances. It also includes the details of the drugs for Alzheimer's in the pipeline and forecast of the company drugs available in the market:
    • Pfizer
    • Eisai
    • Actavis
    • Lundbeck
    • Daiichi Sankyo
    • Novartis
    • TauRx
    • vTv Therapeutics
  • Profiles of leading companies developing diagnostics tests for Alzheimer's disease:
    • Eli Lilly
    • Amarantus Biosciences Holdings
    • Piramal Enterprises
    • GE Healthcare
    • Navidea
    • DiaGenic

image1

  • This report also breaks down the revenue forecast for the Alzheimer's Disease Market by national market:
    • US
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Japan
    • China
    • Brazil
    • India
    • Russia
  • This report covers the qualitative analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market. It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.
  • This report shows transcripts of research interviews conducted by Visiongain:
    • David Hung, Chief Executive Officer of Axovant Sciences Inc.
    • Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare
    • Phyllis Ferrell, Vice President and Alzheimer's Disease Global Platform Leader at Eli Lilly and Co.

Table of Contents

1. Report Overview

  • 1.1 The Alzheimer's Disease Therapeutics and Diagnostics Market Overview
  • 1.2 The Alzheimer's Disease Therapeutics and Diagnostics Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Alzheimer's Disease: An Introduction

  • 2.1 Neurodegenerative Diseases
    • 2.1.1 What is Alzheimer's Disease?
    • 2.1.2 What Causes Alzheimer's Disease?
    • 2.1.2.1 Alzheimer's Disease: Type 3 Diabetes?
    • 2.1.3 Management of Alzheimer's Disease
    • 2.1.4 The Socio-Economic Impact of Alzheimer's Disease
    • 2.1.5 Diagnosis of Alzheimer's Disease

3. Alzheimer's Disease Therapeutics and Diagnostics Market 2017-2027

  • 3.1 Alzheimer's Disease Therapeutics and Diagnostics Market, 2017
  • 3.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
    • 3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
    • 3.2.2 Healthcare Costs for Alzheimer's Disease Will Surpass All Other Medical Expenses
    • 3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
  • 3.3 Drivers and Restraints
  • 3.4 Shift in Focus to Early Disease Stages

4. The Alzheimer's Disease Drugs Market, 2017-2027

  • 4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer's disease
  • 4.2 The Alzheimer's Disease Drugs Market, 2016
  • 4.3 Changing Market Shares of the Leading Alzheimer's Disease Drugs, 2017-2027
  • 4.4 The Alzheimer's Disease Drugs Market Forecast 2017-2027
  • 4.5 Namenda - Forest Laboratories, Subsidiary of Allergan
    • 4.5.1 Namenda Sales Forecast, 2017-2027
  • 4.6 Aricept
    • 4.6.1 Aricept Sales Forecast, 2017-2027
  • 4.7 Exelon
    • 4.7.1 Exelon Sales Forecast, 2017-2027
  • 4.8 Alzheimer's Disease Drugs Pipeline, 2017
    • 4.8.1 New Guidelines: FDA to Relax Rules for the Approval of Alzheimer's Drugs and EMA published new draft guidance for AD treatments
    • 4.8.2 Will Novel Drug Development Strategies Prove Successful?
    • 4.8.3 Solanezumab (Eli Lilly)
    • 4.8.3.1 Solanezumab Sales Forecast 2017-2027
    • 4.8.4 Gantenerumab (Roche)
    • 4.8.4.1 Gantenerumab Pipeline Forecast, 2016-2027
    • 4.8.5 Verubecestat MK-8931 (Merck)
    • 4.8.5.1 Verubecestat MK-8931 Pipeline Forecast, 2016-2027
    • 4.8.6 Idalopirdine Lu AE58054 (Lundbeck)
    • 4.8.7 Azeliragon TTP488 (TransTechPharma)
    • 4.8.8 LMTX (TauRx)
    • 4.8.9 Encenicline EVP-6124 (Forum Pharmaceuticals)
    • 4.8.10 Axona (Accera)
    • 4.8.11 AD-4833 (Takeda Pharmaceuticals)
    • 4.8.12 Intepirdine RVT-101 (Axovant Sciences Ltd)
  • 4.9 Deep Brain Stimulation (Functional Neuromodulation)
  • 4.10 Recent Research on Alzheimer's Disease

5. Leading Companies in the Alzheimer's Disease Drugs Market, 2017

  • 5.1 Pfizer, Inc
    • 5.1.1 Sales and Recent Performance Analysis, 2016
    • 5.1.2 Pfizer: Aricept
    • 5.1.3 Pfizer: R&D Capabilities and Alzheimer's Disease Drug Candidates
  • 5.2 Eisai
    • 5.2.1 Sales and Recent Performance Analysis, 2016
    • 5.2.2 Eisai: Aricept
    • 5.2.3 Eisai: R&D Capabilities and Alzheimer's Disease Drug Candidates
    • 5.2.4 Collaboration with Biogen
    • 5.2.5 Partnership with GE Healthcare for Diagnostic Development
  • 5.3 Forest Laboratories (Acquired by Allergan)
    • 5.3.1 Acquisition by Allergan
    • 5.3.2 Forest: Namenda
    • 5.3.3 Namenda's Sales and Recent Performance Analysis, 2016
  • 5.4 Lundbeck A/S
    • 5.4.1 Sales and Recent Performance Analysis, 2016
    • 5.4.2 Lundbeck: R&D Capabilities
    • 5.4.3 Lundbeck's Alzheimer's Disease Drug Pipeline
    • 5.4.4 Lundbeck: Ebixa
  • 5.5 Daiichi Sankyo
    • 5.5.1 Financial Sales and Recent Performance, 2016
    • 5.5.2 Daiichi Sankyo: Memary
  • 5.6 Novartis AG
    • 5.6.1 Sales and Recent Performance Analysis
    • 5.6.2 Novartis: Exelon
    • 5.6.3 eHealth Programme Delivering Innovation
    • 5.6.4 Novartis: Alzheimer's Disease Drug Pipeline
  • 5.7 TauRx
    • 5.7.1 Partnership with Bayer Schering Pharma AG
  • 5.8 vTv Therapeutics
    • 5.8.1 TTP Translational Technology
    • 5.8.2 vTv Therapeutics: Alzheimer's Disease Pipeline Portfolio

6. The Alzheimer's Disease Diagnostics Market, 2016-2027

  • 6.1 There is Still a Strong Market Need for Effective Diagnosis
  • 6.2 The Alzheimer's Disease Diagnostics Market, 2016
  • 6.3 Changing Market Shares of Leading Alzheimer's Diagnostic Markets, 2016-2027
  • 6.4 The Alzheimer's Diagnostics Market, 2016-2027
  • 6.5 New Criteria and Guidelines to Diagnose Alzheimer's Disease
  • 6.6 Biomarkers for Alzheimer's Disease
    • 6.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
  • 6.7 Alzheimer's Disease: Advances in Diagnostic Imaging Technologies
    • 6.7.1 Structural Imaging
    • 6.7.2 Functional Imaging
    • 6.7.3 Molecular Imaging Technologies
    • 6.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
    • 6.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
    • 6.7.3.3 Flutemetamol (GE Healthcare)
    • 6.7.3.4 Florbetaben (Piramal Imaging)
  • 6.8 Other Alzheimer's Diagnostics in Development
    • 6.8.1 CSF Proteins
    • 6.8.2 Blood Based Biomarkers for Alzheimer's Disease
    • 6.8.3 Genetic Risk Profiling
    • 6.8.4 Eye Tests
    • 6.8.5 Nanoparticles
  • 6.9 Leading Companies in the Alzheimer's Disease Diagnostics Market, 2016
    • 6.9.1 Eli Lilly
      • 6.9.1.1 Recent Performance and Sales Analysis, 2016
      • 6.9.1.2 Alzheimer's Disease Research Effort
      • 6.9.1.3 Solanezumab
      • 6.9.1.4 Lanabecestat
      • 6.9.1.5 Amyvid (Florbetapir F18)
      • 6.9.1.6 Amyvid Receives Marketing Authorization from the European Commission
      • 6.9.1.7 Flortaucipir F-18
      • 6.9.1.8 LY3002813: Phase I
    • 6.9.2 Amarantus BioScience Holdings, Inc.
      • 6.9.2.1 Recent Performance and Sales Analysis, 2014
      • 6.9.2.2 Avant Diagnostics Inc acquire Amarantus Diagnostics Inc
      • 6.9.2.3 LymPro
      • 6.9.2.4 Intellectual Property Acquisitions
    • 6.9.3 Piramal Enterprises
      • 6.9.3.1 Piramal Imaging SA
      • 6.9.3.2 FDA and EMA Approval of Florbetaben
      • 6.9.3.3 Manufacturing and Distribution Agreements
    • 6.9.4 GE Healthcare
      • 6.9.4.1 GE's Commitment to Imaging Research in the Alzheimer's Field
      • 6.9.4.2 Regulatory Approval of Vizamyl - Flutemetamol
      • 6.9.4.3 Licensing Agreements for Flutemetamol
    • 6.9.5 Navidea
      • 6.9.5.1 NAV4694 (Fluorine-18)
      • 6.9.5.2 Collaboration Agreements
      • 6.9.5.3 NAV4694 Clinical Development
    • 6.9.6 DiaGenic

7. The Leading National Markets, 2016-2027

  • 7.1 Regional Breakdown of the Global Alzheimer's Disease Therapeutics and Diagnostic Market, 2016
    • 7.1.1 The US, Japan and Europe Represent More than 80% of the Total Market
  • 7.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Forecast, 2016-2027
  • 7.3 Changing Market Shares of Leading National Markets 2016-2027
  • 7.4 The US Alzheimer's Disease Therapeutics and Diagnostics Market, 2016-2027
    • 7.4.1 One in Nine Over the Age of 65 has AD in the US
    • 7.4.2 The US Will Remain the Largest Market Over the Forecast Period
  • 7.5 The European Alzheimer's Disease Therapeutics and Diagnostics Market, 2016-2027
    • 7.5.1 The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
    • 7.5.2 The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
    • 7.5.3 The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
    • 7.5.4 The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
    • 7.5.5 The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
    • 7.5.6 The Rest of Europe Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
  • 7.6 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
  • 7.7 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
  • 7.8 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
  • 7.9 The Brazilian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
  • 7.10 The Russian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
  • 7.11 The Rest of the World Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2016-2027

8. Qualitative Analysis of the Alzheimer's Disease: Therapeutics and Diagnostics Market, 2016-2027

  • 8.1 SWOT Analysis
  • 8.2 Strengths
    • 8.2.1 Alzheimer's Disease is a High-Profile Disease
    • 8.2.2 Expanding Patient Population
    • 8.2.3 Strong R&D Pipeline in Both Sectors of the Market
  • 8.3 Weaknesses
    • 8.3.1 Current Drugs Only Treat the Symptoms of Alzheimer's Disease
    • 8.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
    • 8.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
  • 8.4. Opportunities
    • 8.4.1 Regulations Seeking Improved Standards of Alzheimer's Disease Drug Development
    • 8.4.2 Neurodegenerative Diseases Have Strong R&D
    • 8.4.3 Emerging Markets Will Help Drive the Market
    • 8.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
  • 8.5 Threats
    • 8.5.1 Patent Expiries Will Lead to Further Generic Competition
    • 8.5.2 New AD Therapies Face Political, Commercial and Social Pressures
  • 8.6 Porter's Five Force Analysis
    • 8.6.1 Rivalry Among Competitors
    • 8.6.2 Threats of New Entrants
    • 8.6.3 Powers of Suppliers
    • 8.6.4 Bargaining Power of Buyers
    • 8.6.5 Threat of Substitutes

9. Research Interviews

  • 9.1 Interview with David Hung, M.D., CEO of Axovant Sciences Inc.
    • 9.1.1 Axovant Sciences Inc
    • 9.1.2 Intepirdine for The Treatment of Alzheimer's Disease
    • 9.1.3 Intepirdine for The Treatment of Lewy Body Dementia
    • 9.1.4 Candidates in Phase 1 for Alzheimer's Disease
  • 9.2 Interview with Gill Farrar, PhD, Scientific Director, PET Neurology - Medical Affairs at GE Healthcare
    • 9.2.1 GE Healthcare
    • 9.2.2 Progress in Alzheimer's Research
    • 9.2.3 Global Alzheimer's Diagnostics Market
    • 9.2.4 Broadening Vizamyl's Use
    • 9.2.5 New EMA Guidelines to Include Early Disease Stages
  • 9.3 Interview with Phyllis Ferrell, Vice President and Alzheimer's Disease Global Platform Leader at Eli Lilly and Co.
    • 9.3.1 Eli Lilly and Co.
    • 9.3.2 Global Alzheimer's Disease Therapeutics market
    • 9.3.3 Eli Lilly's Pipeline, Drugs and Diagnostics for Alzheimer's Disease
    • 9.3.4 Amyvid and Challenges in Developing Biomarkers

10. Conclusion

  • 10.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
  • 10.2 Disease Modifying Drugs Will Transform the Declining Alzheimer's Market
  • 10.3 Demographics Will Help Drive the Market Over the Forecast Period
  • 10.4 Medicines and Diagnostic Tests for Alzheimer's Disease Hold Great Potential from 2016 to 2027
  • 10.5 Research for Alzheimer's Happening across the World

Appendices

  • Some Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 Leading Sectors in The Neurodegenerative Disease Market, 2016
  • Table 2.2 Imaging Technologies Used in Alzheimer's Research, 2017
  • Table 3.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Sector, 2016
  • Table 3.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 3.3 The Alzheimer's Disease Therapeutics and Diagnostics Market: Drivers and Restraints, 2016
  • Table 4.1 The Alzheimer's Disease Drugs Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2016
  • Table 4.2 Market Shares (%) of the Leading Alzheimer's Drugs, 2016, 2021, 2027
  • Table 4.3 The Alzheimer's Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.4 Namenda: Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.5 Aricept: Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.6 Exelon: Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.7 Alzheimer's Disease Drugs in the Pipeline Phase 3, 2017
  • Table 4.8 Disease Drugs in the Pipeline Phase 2, 2017
  • Table 4.9 Alzheimer's Disease Drugs in the Pipeline Phase 1 2017
  • Table 4.10 Solanezumab Clinical Trial Results
  • Table 4.11 Eli Lilly: Solanezumab Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.12 Roche: Gantenerumab Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.13 Verubecestat Clinical Trial Results
  • Table 4.14 Merck: Verubecestat MK-8931 Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.15 Idalopirdine Clinical Trial Results
  • Table 5.1 Pfizer: Revenues ($bn) and Revenue Shares (%) by Sector, 2016
  • Table 5.2 Pfizer: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 5.3 Pfizer: Alzheimer's Disease Drug Pipeline, 2017
  • Table 5.4 Eisai: Aricept Regional Sales ($m), AGR (%), 2013
  • Table 5.5 Eisai: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 5.6 Biogen: Alzheimer's Disease Drugs Pipeline, 2017
  • Table 5.7 Forest: Namenda's Historical Revenues ($bn) and AGR (%), 2010-2015
  • Table 5.8 Allergan: Namenda Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 5.9 Lundbeck: Revenue ($bn) and Revenue Share (%) by Region, 2016
  • Table 5.10 Ebixa: Revenue ($bn) and Revenue Share (%) by Region, 2016
  • Table 5.11 Ebixa: Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 5.12 Daiichi Sankyo: Memary Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 5.13 Novartis: Revenue ($bn) and Revenue Shares (%) by Segment, 2016
  • Table 5.14 vTv Therapeutics: Alzheimer's Disease Drugs Pipeline, 2016
  • Table 6.1 The Alzheimer's Disease Diagnostics Market:Revenues ($bn) and Market Shares (%) by Segment, 2016
  • Table 6.2 Market Shares (%) of the Leading Alzheimer's Diagnostics Markets, 2016, 2021 and 2027
  • Table 6.3 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Segment, 2016-2027
  • Table 6.4 Key Alzheimer's Diagnostic Tests in Development, 2017
  • Table 6.5 Eli Lilly Pipeline Including Drugs and Diagnostics for Alzheimer's Disease
  • Table 6.6 DiaGenic: Alzheimer's Disease Diagnostics Pipeline, 2016
  • Table 7.1 The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Share (%) by Region, 2016
  • Table 7.2 The Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2016-2027
  • Table 7.3 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast CAGR (%), 2016-2021, 2021-2027, 2016-2027
  • Table 7.4 Market Shares (%) of the Leading Regional Alzheimer's Disease Therapeutics and Diagnostics Markets, 2016, 2021 and 2027
  • Table 7.5 The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.6 The European Alzheimer's Therapeutics and Diagnostics Market: Revenue ($bn), European Market Share (%) and Global Market Share (%) by Leading Countries, 2016
  • Table 7.7 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.8 The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.9 The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2016-2027
  • Table 7.10 The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2016-2027
  • Table 7.11 The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.12 The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.13 The Rest of Europe Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.14 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.15 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.16 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.17 The Brazilian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.18 The Russian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 7.19 The Rest of the World Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 8.1 SWOT Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2016
  • Table 10.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2016, 2021 and 2027 and CAGR (%) 2016-2021 and 2021-2027 by Region
  • Table 10.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market ($bn) by Sector, 2016, 2021 and 2027

List of Figures

  • Figure 1.1 Alzheimer's Disease Therapeutics and Diagnostics:Overview of Submarkets and Segments
  • Figure 3.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Sector, 2016
  • Figure 3.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Market Share (%) by Sector, 2016
  • Figure 3.3 The Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 3.4 Current Stage in Research and Development for Alzheimer's Disease
  • Figure 4.1 The Alzheimer's Disease Drugs Market: Revenues ($bn) by Leading Drugs, 2016
  • Figure 4.2 The Alzheimer's Disease Drugs Market: Market Shares (%) by Leading Drugs, 2016
  • Figure 4.3 The Alzheimer's Therapeutics Market: Market Shares (%) by Drug, 2021
  • Figure 4.4 The Alzheimer's Therapeutics Market: Market Shares (%) by Drug, 2027
  • Figure 4.5 The Alzheimer's Disease Drugs Market Forecast: Revenue ($bn), 2016-2027
  • Figure 4.6 Namenda: Sales Forecast ($bn), 2016-2027
  • Figure 4.7 Aricept: Sales Forecast ($bn), 2016-2027
  • Figure 4.8 Exelon: Sales Forecast ($bn), 2016-2027
  • Figure 4.9 Eli Lilly: Solanezumab Sales Forecast ($bn), 2016-2027
  • Figure 4.10 Roche: Gantenerumab Sales Forecast ($bn), 2016-2027
  • Figure 4.11 Merck: MK-8931 Sales Forecast ($bn), 2016-2027
  • Figure 5.1 Pfizer: Historical Revenues ($bn), 2012-2016
  • Figure 5.2 Pfizer: Revenues ($bn) by Sector, 2016
  • Figure 5.3 Pfizer: Revenue Shares (%) by Sector, 2016
  • Figure 5.4 Pfizer: Aricept Sales Forecast ($bn), 2016-2027
  • Figure 5.5 Pfizer: Historical R&D Expenditure ($bn), 2012-2016
  • Figure 5.6 Eisai: Aricept Historical Revenue ($bn) 2013-2016
  • Figure 5.7 Eisai: Aricept Sales Forecast ($bn), 2016-2027
  • Figure 5.8 Eisai: Historical R&D Expenditure ($bn), 2013-2015
  • Figure 5.9 Forest: Namenda's Historical Revenue ($bn), 2010-2015
  • Figure 5.10 Allergan: Namenda Sales Forecast ($bn), 2016-2027
  • Figure 5.11 Lundbeck: Revenue Share (%) by Region, 2016
  • Figure 5.12 Lundbeck: Revenue Share ($bn) by Region, 2016
  • Figure 5.13 Lundbeck: R&D Expenditure ($bn), 2015-2016
  • Figure 5.14 Ebixa: Revenue ($bn) by Region, 2016
  • Figure 5.15 Ebixa: Revenue Shares (%) by Region, 2016
  • Figure 5.16 Ebixa: Sales Forecast ($bn), 2016-2027
  • Figure 5.17 Daiichi Sankyo: Historical Revenue ($bn), 2012-2015
  • Figure 5.18 Daiichi Sankyo: Memary Historical Revenue ($bn), 2013-2015
  • Figure 5.19 Daiichi Sankyo: Memary Sales Forecast ($bn), 2016-2027
  • Figure 5.20 Novartis: Historical Revenues ($bn), 2012-2016
  • Figure 5.21 Novartis: Revenues ($bn) by Segment, 2016
  • Figure 5.22 Novartis: Revenue Shares (%) by Segment, 2016
  • Figure 5.23 Exelon: Historical Revenue Shares (%) by Region, 2016
  • Figure 6.1 The Alzheimer's Disease Diagnostics Market: Revenues ($bn) by Segment, 2016
  • Figure 6.2 The Alzheimer's Disease Diagnostics Market: Market Shares (%) by Segment, 2016
  • Figure 6.3 The Alzheimer's Diagnostics Market: Market Share (%) by Segment, 2021
  • Figure 6.4 The Alzheimer's Diagnostics Market: Market Share (%) by Segment, 2027
  • Figure 6.5 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), 2016-2027
  • Figure 6.6 Eli Lilly: Historical Revenue ($bn), 2012-2016 2012-2016
  • Figure 6.7 AmarantusBioScience: R&D Costs ($m), 2014-2015
  • Figure 6.8 Piramal Enterprise Historical Revenue by Business Unit 2015-2016
  • Figure 6.9 GE Healthcare Historical Revenues ($bn) 2014-2016
  • Figure 7.1 The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, 2016
  • Figure 7.2 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2016-2021
  • Figure 7.3 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2021-2026
  • Figure 7.4 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2016-2027
  • Figure 7.5 The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2021
  • Figure 7.6 The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2027
  • Figure 7.7 The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.8 The US Demographics: No. of People Aged 65 or Over, 2015 and 2030 Forecast
  • Figure 7.9 The European Alzheimer's Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Leading Countries, 2016
  • Figure 7.10 The European Alzheimer's Disease Therapeutics and Diagnostics Market: Market Shares (%) by Leading Countries, 2016
  • Figure 7.11 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.12 The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.13 The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.14 The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.15 The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.16 The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.17 The Other European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.18 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.19 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.20 China's Historical Healthcare Expenditure ($bn), 2001-2010
  • Figure 7.21 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.22 The Brazilian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.23 The Russian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 7.24 The Rest of the World Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
  • Figure 8.1 The Global Over 65 Population: Forecast (millions), 2010-2050
  • Figure 8.2 Porter's Five Force Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2016
  • Figure 10.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2016, 2021 and 2027
  • Figure 10.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market ($bn) by Segment, 2016, 2021 and 2027

Companies Listed

  • AbbVie
  • AB Science
  • AC Immune
  • Acadia Pharmaceuticals
  • Accera
  • Actavis
  • Adamas Pharmceuticals
  • Affiris
  • Allergan
  • Amarantus BioSciences
  • Amorphis
  • Amgen
  • Archer Pharmaceuticals
  • Astellas Pharma
  • Astex
  • AstraZeneca
  • Avanir Pharmaceuticals
  • Avineuro Pharmaceuticals
  • Axovant Sciences Inc
  • AZ Therapies Inc
  • Baxter
  • Bayer
  • Bayer Schering Pharma
  • Biogen
  • bioMerieux
  • Boehringer Ingelheim
  • Bristol Myers Suibb
  • Ceregene
  • Chiesi Farmaceutici
  • Cognoptix
  • Cytos
  • Daiichi Sankyo
  • DiaGenic
  • Eisai
  • Elan
  • Eli Lilly
  • EnVivo Pharmaceuticals
  • European Medicines Agency (EMA)
  • Forest Laboratories
  • Forum Pharmaceuticals
  • Foundation Medical Partners
  • Functional Neuromodulation
  • Food and Drug Administration (FDA)
  • GE Healthcare
  • General Electric
  • Genervon Biopharmaceuticals
  • Genesys Capital
  • GSK
  • Hisamitsu Pharmaceutical
  • Humanetics
  • IBA Molecular
  • J&J
  • Janssen Alzheimer Immunotherapy Research & Development
  • Janssen Pharmaceutical K. K
  • Kareus Therapeutics
  • LabCorp
  • Luminex
  • Lundbeck
  • Medtronic
  • Merck & Co
  • Merz
  • Meso Scale Diagnostics
  • Metabolic Solutions Development Company
  • MorphoSys
  • Nanotherapeutics
  • National Institute of Health (NIH)
  • National Institute for Health and Care Excellence (NICE)
  • Navidea
  • NextGen Sciences
  • Novartis
  • Novo Nordisk
  • Ono Pharmaceutical
  • OPKO
  • Ortho Clinical Diagnostics
  • Otsuka Pharmaceutical
  • Oxford BioDynamics
  • Par Pharmaceuticals
  • Pfizer
  • Piramal Enterprises
  • Piramal Imaging
  • Proteome Sciences
  • ProteoTech
  • Proterra
  • QR Pharma
  • Quanterix
  • Raptor Pharmaceutical
  • Resverlogix
  • Roche
  • Roche Diagnostics
  • Saladax
  • Sandoz
  • Sangamo BioSciences
  • Sanofi
  • sGC Pharma
  • Shionogi
  • Shire
  • Siemens Medical Solutions USA
  • Somalogic
  • Sonexa Therapeutics
  • Sun Pharma
  • T3D Therapeutics
  • Takeda
  • Targacept
  • TauRx
  • Toyama Chemical
  • Transition Therapeutics
  • TransTech Pharma
  • United Biomedical
  • VIVUS
  • Wyeth
Back to Top